IHC testing verified that the TIMELESS expression of the TIMELESS protein was moderately positive in breast cancer, lung cancer, and renal cancer (Fig. 10a–c) from clinical cancer specimens. This evidence concerns the gene TIMELESS and breast carcinoma.